구조모아 (StructureMoa)항암 chemical structure spider web
방문Cytochrome P450 (CYP) Cocktail(Amgen)은 Metastatic Castration-resistant Prostate 표적 치료제로, Metastatic Castration-resistant Prostate Cancer; Prostate Cancer 영역에서 개발·상용화 중입니다. 작용기전: inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 12.79% (ClinicalTrials.gov NCT05981365). 차별점: novel regulatory axis that involves PTX3, miR-1255b-2-3p, and CYP2J2 and drives the progression of OSCC, highlighting PTX3 as.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Metastatic Castration-resistant Prostate
Metastatic Castration-resistant Prostate Cancer; Prostate Cancer
Discontinued
2026-09-02
Data Confidence · Low
Development Signal · Watch
Humanized mouse models for drug metabolism and drug transport: a systematic review
novel regulatory axis that involves PTX3, miR-1255b-2-3p, and CYP2J2 and drives the progression of OSCC, highlighting PTX3 as
inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway
Immune-Mediated Diseases: A Prospective Observational Study
topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2-targeted antibody-drug conjugate (
biomarker in OSCC management
resistance mechanisms to achieve species-specific eradication, offering a promising strategy to combat multidrug-resistant infections and al
구조화 데이터
xenograft model
rat
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Cytochrome P450 (CYP) Cocktail(Amgen)은 Metastatic Castration-resistant Prostate 표적 치료제로, Metastatic Castration-resistant Prostate Cancer; Prostate Cancer 영역에서 개발·상용화 중입니다. 작용기전: inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 12.79% (ClinicalTrials.gov NCT05981365). 차별점: novel regulatory axis that involves PTX3, miR-1255b-2-3p, and CYP2J2 and drives the progression of OSCC, highlighting PTX3 as.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Metastatic Castration-resistant Prostate
Metastatic Castration-resistant Prostate Cancer; Prostate Cancer
Discontinued
2026-09-02
Data Confidence · Low
Development Signal · Watch
Humanized mouse models for drug metabolism and drug transport: a systematic review
novel regulatory axis that involves PTX3, miR-1255b-2-3p, and CYP2J2 and drives the progression of OSCC, highlighting PTX3 as
inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway
Immune-Mediated Diseases: A Prospective Observational Study
topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2-targeted antibody-drug conjugate (
biomarker in OSCC management
resistance mechanisms to achieve species-specific eradication, offering a promising strategy to combat multidrug-resistant infections and al
구조화 데이터
xenograft model
rat
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.